The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Is it possible to halve the incidence of liver cancer in China by 2050?
Open accessAbstract
A substantial proportion of liver cancers is attributable to chronic infection with hepatitis B and C (HBV/HCV). Liver cancer could become the second cancer, after cervical, to be effectively controlled globally, if proven interventions such as vaccination can be implemented on a large scale. In 2018, the global mortality rate for liver cancer was estimated to be 8.5 per 100 000 individuals. Given patterns of HBV infection and immigration across countries, liver cancer control requires combined, global action. Liver cancer trends vary between countries, in some Western countries, the incidence rates were relatively low but have increased in recent decades; conversely, in several Asian countries, the incidence rates have decreased over time. China has in the past contributed more than half of the global burden of liver cancer but more recently a national decline in liver cancer incidence has been observed. Here, we review the liver cancer burden and exposure to risk factors in China, compared to other countries. We also review the implementation status for primary and secondary prevention interventions and major outcomes achieved over the past three decades. Using Bayesian age‐period‐cohort analysis, we examine recent trends and based on these, predict that by 2050, the incidence of liver cancer in China could fall by half. We additionally survey the literature to identify current research needs, and review relevant national policies on liver cancer control in China. A comprehensive set of interventions is proposed to progress toward the long‐term goal of liver cancer elimination based on the natural history and evidence‐based interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Self-citationRoth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600
Self-citationAllemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145
Self-citationA meta-analysis of alcohol consumption and the risk of 15 diseases
Corrao, G. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2003.11.027 · Cited by 1,077 · cited 1×
“19) for 25, 50 and 100 g of alcohol intake per day, respectively.(32) Based on WHO data, in”
BackgroundWhite, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766 · cited 1×
“8% over 3 years.(37) The GBD 2017 also estimated the contribution of NASH and cirrhosis due to NASH to liver cancer and the percentages in overall deaths at any age were estimated as 0.”
BackgroundSimms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J.-B., Soerjomataram, I., Castle, P. E., Bray, F., & Canfell, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30836-2 · Cited by 486
Self-citationPopulation attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis
Liu, Y., Chang, C.-C. H., Marsh, G. M., & Wu, F. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.009 · Cited by 372
Cited by
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L.-H., Chow, P. K.-H., & Ngeow, J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.033 · Cited by 583
Cancer burden in China: trends, risk factors and prevention
Sun, D., Li, H., Cao, M., He, S., Lei, L., Peng, J., & Chen, W. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0387 · Cited by 255
Self-citation
Metadata
- Authors
- Shi, J., Cao, M., Wang, Y., Bai, F., Lei, L., Peng, J., Feletto, E., Canfell, K., Qu, C., & Chen, W.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2020-10-16
- Volume
- 148
- Issue
- 5
- Pages
- 1051-1065
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W3091233587
- Cited by
- 177
- References
- 7
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is it possible to halve the incidence of liver cancer in China by 2050? https://app.cochat.ai/papers/10.1002/ijc.33313
- The paper
- Shi, J., Cao, M., Wang, Y., Bai, F., Lei, L., Peng, J., Feletto, E., Canfell, K., Qu, C., & Chen, W. (2021). Is it possible to halve the incidence of liver cancer in China by 2050? International Journal of Cancer. https://doi.org/10.1002/ijc.33313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.